From 06c33821011a1adc622533c0c313e2b479b2b6e7 Mon Sep 17 00:00:00 2001 From: Georg Zeller Date: Mon, 18 Nov 2024 18:02:31 +0100 Subject: [PATCH] Update 2024-02-01-conti-gabriele.md --- team/_posts/2024-02-01-conti-gabriele.md | 4 +--- 1 file changed, 1 insertion(+), 3 deletions(-) diff --git a/team/_posts/2024-02-01-conti-gabriele.md b/team/_posts/2024-02-01-conti-gabriele.md index 9340b245..a2b1c37f 100644 --- a/team/_posts/2024-02-01-conti-gabriele.md +++ b/team/_posts/2024-02-01-conti-gabriele.md @@ -19,6 +19,4 @@ twitter: ContiGabriele96 scholar: qM8-P_UAAAAJ --- -Gabriele holds BSc and MSc degrees in Biotechnology and Pharmaceutical Biotechnology, respectively, from the Alma Mater Studiorum University of Bologna (Italy), where he is currently a Ph.D. student in the Biotechnological Biocomputational Pharmaceutical Sciences program. His research focuses on the role of the human microbiome in various oncological diseases. Using biocomputational and biostatistical approaches to analyse next-generation sequencing (NGS) microbiome data, his work aims to develop personalised integrated intervention strategies for patients, with a particular focus on haematological malignancies in both adult and paediatric populations. - -During his visiting period at LUMC, Gabriele focused on a paediatric cohort affected by various haematological malignancies to assess the role of the gut microbiome in allo-HSCT therapy. He investigated the interaction of the gut microbiome with disease remission and progression, as well as side effects such as aGvHD and febrile neutropenia. +Gabriele visited the Zeller group at the LUMC between 2024-02-01 and 2024-07-31 while doing his PhD research at the University of Bologna (Italy) in the Biotechnological Biocomputational Pharmaceutical Sciences program.